New Link Established Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agent
The Wnt signaling pathway modulates the response to inhibitors of autophagy as potential adjuvants in melanoma
Newswise — PHILADELPHIA — (Sept. 7, 2017) — Results of a study by The Wistar Institute have described a correlation between a key melanoma signaling pathway and a novel class of drugs being tested in the clinic as adjuvant therapy for advanced melanoma, providing useful information for a more effective use of this type of treatment. The study was published online in Cancer Research.
Melanoma is the deadliest form of skin cancer. In recent years, there has been a large effort for the development of targeted therapies that inhibit specific signaling pathways required for proliferation of tumor cells and melanoma progression. However, the effectiveness of this therapeutic approach is only temporary, as tumors eventually become resistant, emphasizing the need for other therapeutic options.
Autophagy is a metabolic process that provides resources for the synthesis of new macromolecules through the degradation of cellular constituents. It allows cancer cells to survive under stressful conditions in the tumor microenvironment. Because it also affects the response to melanoma targeted therapy, several studies are investigating the potential of inhibiting autophagy as a strategy to improve sensitivity to targeted therapy, with some autophagy inhibitors currently moving into clinical trials. This latest Wistar study provides important, new information on the interplay of autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis.
“We have already shown that Wnt5A, a component of the Wnt pathway, plays critical roles in melanoma progression,” said Ashani Weeraratna, Ph.D., Ira Brind Associate Professor and co-program leader of the Immunology, Microenvironment and Metastasis Program at Wistar and corresponding author of the paper. “Our new study indicates a link between the Wnt pathway and autophagy, whereby Wnt is a key player in the response to autophagy inhibitors and likely affects the efficacy of this class of drugs.”
Weeraratna and colleagues assessed the interplay between Wnt5A, a key molecule in the Wnt pathway, and autophagy by combining expression studies in human melanoma biopsies with functional analyses
in cell lines and mouse models. In particular, they found a direct correlation between expression levels of Wnt5A, which also correlate with melanoma progression, and activation of autophagy. They then observed a reciprocal regulation of autophagy and Wnt signaling. This prompted them to test in vitro and in vivo how the response of melanoma to an autophagy inhibitor is affected by Wnt signaling activation.
They observed that cells with high levels of Wnt5A and autophagy activation are less sensitive and require higher concentrations of the inhibitor. They also found that the pharmacological modulation of another molecule of the Wnt pathway, β-catenin, significantly improves the response of aggressive melanoma cells to autophagy inhibition, lowering the dose required to eradicate these cells.
“By dissecting the crosstalk between the autophagy pathway and the Wnt pathway, we discovered that signaling changes that occur within the tumor may affect the response to autophagy inhibitors,” said Abibatou Ndoye, a graduate student in the Weeraratna lab and first author of the study. “Our observations will be helpful to determine which patients will be more responsive to this therapeutic strategy and how we can target the pathways that affect the response, in order to overcome resistance.”
Through the new link established between autophagy and Wnt, the study also proposes a novel role of autophagy in melanoma invasion and suggests that autophagy inhibitors may be useful in melanoma treatment beyond their ability to render the cells more sensitive to targeted therapy.
This work was supported by National Institutes of Health grants R01 CA174746, P01 CA114046, P50 CA174523, T32 CA009171, K99 CA208012-01, R01 CA169134M, R01 CA139319; additional funds were provided by a Melanoma Research Alliance/L’Oréal Paris-USA Women in Science Team Science Award, a gift from the Adelson Medical Research Foundation, and the Ira Brind Associate Professorship to Weeraratna. Core support for The Wistar Institute and The University of Texas MD Anderson Cancer Center was provided by the Cancer Center Support Grants P30CA010815 and P30 CA16672.
Co-authors of this study from The Wistar Institute include Anna Budina-Kolomets, Curtis H. Kugel III, Marie Webster, Amanpreet Kaur, Reeti Behera, Ling Li, Patricia Brafford, Qin Liu, Meenhard Herlyn, and Maureen Murphy. Other co-authors include Vito Rebecca, Xiaowei Xu, Michael Nicastri, Jeffrey Winkler, and Ravi Amaravadi from the University of Pennsylvania; Y.N. Vashisht Gopal, Michael A. Davies, and Gordon B. Mills from The University of Texas MD Anderson Cancer Center; Hong Wu from the Fox Chase Cancer Center; and Maria S. Soengas from the Spanish National Cancer Research Centre, Madrid, Spain.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.